Updates are available Correction dated 2024-05-24
Click to view Correction: https://doi.org/10.1007/s40257-024-00864-1
Updates are available Correction dated 2025-09-11
Click to view Correction: https://doi.org/10.1007/s40257-025-00976-2
Updates are available Correction dated 2026-06-18
Click to view Correction: https://doi.org/10.1007/s40257-026-01051-0
-
Authors
King, Brett
Soung, Jennifer
Tziotzios, Christos
Rudnicka, Lidia
Joly, Pascal
Gooderham, Melinda
Sinclair, Rodney
Mesinkovska, Natasha A.
Paul, Carle
Gong, Yankun
Anway, Susan D.
Tran, Helen
Wolk, Robert
Zwillich, Samuel H.
Lejeune, Alexandre
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02974868 at ClinicalTrials.govnct04517864 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
New drugs under investigation for the treatment of alopecias
https://doi.org/10.1080/13543784.2019.1568989
nct03732807 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
nct04006457 at ClinicalTrials.govDocuments that mention this clinical trial
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
https://doi.org/10.1007/s40257-024-00899-4
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
https://doi.org/10.1007/s13555-024-01260-7
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
https://doi.org/10.1007/s40262-023-01318-3
Documents that mention this clinical trial
Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
https://doi.org/10.1007/s13555-025-01648-z
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 16 January 2024
First Online: 23 January 2024
Change Date: 13 June 2026
Change Type: Update
Change Details: The original online version of this article was revised due to update in Table 2.
Change Date: 24 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40257-024-00864-1
Change Date: 18 June 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40257-026-01051-0
Change Date: 11 September 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40257-025-00976-2
Declarations
:
: This study was sponsored by Pfizer Inc.
: Brett King: AbbVie, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Equillium, Horizon Therapeutics, Eli Lilly, Incyte, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra, Pfizer, Regeneron, Sanofi Genzyme, TWi Biotechnology, and Viela Bio. He has served on speaker bureaus for Pfizer. Jennifer Soung: speaker for Regeneron/Sanofi and Ortho Dermatologics; speaker and investigator for Amgen, AbbVie, and Pfizer; speaker, investigator, and advisor for Eli Lilly; investigator and advisor for LEO Pharma; investigator, speaker, and consultant for Novartis; investigator for UCB, Janssen, Kyowa Kirin, KoBio Labs, and Castel Biosciences; investigator and consultant for Dermavant; speaker and consultant for Bristol Myers Squibb, speaker, investigator and consultant for Arcutis. Christos Tziotzios: speaker for LEO Pharma; principal and chief investigator for Pfizer; consultant for Pfizer. Lidia Rudnicka: speaker for AbbVie, L'Oreal, LEO Pharma, Novartis, Pierre Fabre, and Pfizer; advisory board member for LEO Pharma, Janssen, L'Oreal, Novartis, Pfizer, Sanofi, and UCB. Pascal Joly: consultant for Amgen, Argenx, AstraZeneca, Innovaderm, Principia Biopharma, Roche, Sanofi-Regeneron Pharmaceuticals, Thermo Fisher Scientific, Novartis, Pfizer, Lilly, AbbVie, and Janssen Cilag. Melinda Gooderham: investigator, speaker, and/or advisor for AbbVie, Amgen, Akros, AnaptysBio, Arcutis, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, and UCB. Rodney Sinclair: professional services to Aerotech, AbbVie, AstraZeneca, Akesobio, Amgen, Arcutis, Arena, Ascend, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Coherus Biosciences, Connect, Cutanea, Demira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, MedImmune, Merck, MSD, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone, Roche, Samson Clinical, Sanofi, Sun Pharma, and UCB. Natasha A. Mesinkovska: professional services to AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly, La Roche Posay, and Pfizer. Carle Paul: consulting fees and/or grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, GSK, Janssen Cilag, LEO Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi, and UCB Pharma. Yankun Gong, Helen Tran, Robert Wolk, Samuel H. Zwillich, and Alexandre Lejeune are employees of, and hold stock or stock options in, Pfizer. Susan D. Anway was an employee of Pfizer at the time of the study and holds stock or stock options in Pfizer.
: Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See for more information.
: Ethics approval was obtained for individual studies included in this integrated safety analysis. The study was performed in accordance with the ethical standards as provided in the Declaration of Helsinki.
: Informed consent was obtained from all participants of the individual studies included in this integrated safety analysis.
: Patients signed informed consent regarding publishing their data.
: Not applicable.
: All authors contributed to the concept and design of the study, to data analysis and interpretation, to critical revision of the publication, and all authors read and approved the final manuscript.
